External validation of precisebreast, a digital prognostic test for predicting breast cancer recurrence, in an early-stage cohort from the Netherlands.

Journal: Breast cancer research : BCR
Published Date: Aug 20, 2025

Abstract

BACKGROUND: Current clinical guidelines recommend gene expression profiling to guide treatment in early-stage breast cancer. PreciseBreast (PDxBR) is a digital prognostic tool that integrates artificial intelligence (AI)-derived features from hematoxylin and eosin (H&E) slides with clinicopathologic data to predict recurrence risk. This study externally validated PDxBR in an independent cohort and compared its performance to other risk models.

Authors

  • Pieter J Westenend
    Laboratory of Pathology, Dordrecht, Netherlands.
  • Claudia Meurs
    Laboratory of Pathology, Dordrecht, Netherlands.
  • Gerardo Fernandez
    Department of Pathology, Icahn School of Medicine at Mount Sinai, New York, NY, 10029, USA.
  • Marcel Prastawa
    Department of Pathology, Icahn School of Medicine at Mount Sinai, New York, NY, 10029, USA.
  • Abishek Sainath Madduri
    PreciseDx, Inc., New York, NY, USA.
  • Aaron Feliz
    PreciseDx, Inc., New York, NY, USA.
  • Juan Carlos Mejias
    PreciseDx, Inc., New York, NY, USA.
  • Alexander Shtabsky
    PreciseDx, Inc., New York, NY, USA.
  • Xiaozhu Zhang
    Biofourmis Singapore Pte. Ltd, Singapore, Singapore.
  • Brandon Veremis
    Department of Pathology, Molecular and Cell-based Medicine, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
  • Rebecca DeAngel
    PreciseDx, Inc., New York, NY, USA.
  • Michael J Donovan
    Department of Pathology, Icahn School of Medicine at Mount Sinai, New York, NY, 10029, USA.

Keywords

External Resources

Popular Topics
Recent Journals